[go: up one dir, main page]

NO20080585L - Immunological adjuvant emulsion - Google Patents

Immunological adjuvant emulsion

Info

Publication number
NO20080585L
NO20080585L NO20080585A NO20080585A NO20080585L NO 20080585 L NO20080585 L NO 20080585L NO 20080585 A NO20080585 A NO 20080585A NO 20080585 A NO20080585 A NO 20080585A NO 20080585 L NO20080585 L NO 20080585L
Authority
NO
Norway
Prior art keywords
oil
emulsion
nonionic surfactant
adjuvant emulsion
relates
Prior art date
Application number
NO20080585A
Other languages
Norwegian (no)
Other versions
NO336369B1 (en
Inventor
Marie-Francoise Klucker
Francois Dalencon
Patricia Probeck-Quellec
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0507240A external-priority patent/FR2888117B1/en
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of NO20080585L publication Critical patent/NO20080585L/en
Publication of NO336369B1 publication Critical patent/NO336369B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)

Abstract

Oppfinnelsen angår en termoreversibel olje-i-vann adjuvansemulsjon omfattende minst: skvalen; et vandig løsningsmiddel; en ikke-ionisk surfaktant som er i fonn av en polyoksyetylenalkyleter; og en hydrofob ikke-ionisk surfaktant, der 90 % av populasjonen basert på volumet av oljedråpene er mindre enn 200 nm i størrelse. Oppfinnelsen angår også en fremgangsmåte for å fremstille en immunogen sammensetning, der minst et vaksineantigen blandes med en olje-i-vann emulsjon. Oppfinnelsen kjennetegnes ved at olje-i-vann emulsjonen oppnås ved anvendelse av en fremgangsmåte som involverer faseinversjon ved hjelp av temperaturvariasjon.The invention relates to a thermoreversible oil-in-water adjuvant emulsion comprising at least: squalene; an aqueous solvent; a nonionic surfactant found in a polyoxyethylene alkyl ether; and a hydrophobic nonionic surfactant, where 90% of the population based on the volume of the oil droplets is less than 200 nm in size. The invention also relates to a process for preparing an immunogenic composition wherein at least one vaccine antigen is mixed with an oil-in-water emulsion. The invention is characterized in that the oil-in-water emulsion is obtained using a method involving phase inversion by means of temperature variation.

NO20080585A 2005-07-07 2008-01-31 Oil-in-water adjuvant emulsion, use and method of preparation thereof, as well as immunogenic composition and method of preparation thereof. NO336369B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0507240A FR2888117B1 (en) 2005-07-07 2005-07-07 VACCINE COMPOSITION COMPRISING A THERMOREVERSIBLE EMULSION
FR0508310 2005-08-04
PCT/FR2006/001635 WO2007006939A2 (en) 2005-07-07 2006-07-07 Thermoreversible immuno-adjuvant emulsion

Publications (2)

Publication Number Publication Date
NO20080585L true NO20080585L (en) 2008-03-26
NO336369B1 NO336369B1 (en) 2015-08-10

Family

ID=37637538

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080585A NO336369B1 (en) 2005-07-07 2008-01-31 Oil-in-water adjuvant emulsion, use and method of preparation thereof, as well as immunogenic composition and method of preparation thereof.

Country Status (24)

Country Link
EP (2) EP2080522B1 (en)
JP (1) JP5300475B2 (en)
KR (1) KR101328638B1 (en)
CN (1) CN101217977B (en)
AR (1) AR054822A1 (en)
AT (1) ATE424845T1 (en)
AU (1) AU2006268466B2 (en)
BR (1) BRPI0614053A2 (en)
CA (1) CA2613732C (en)
CY (2) CY1108994T1 (en)
DE (1) DE602006005671D1 (en)
DK (2) DK2080522T3 (en)
EA (1) EA012376B1 (en)
ES (2) ES2390104T3 (en)
IL (1) IL187967A0 (en)
MX (1) MX2007016412A (en)
NO (1) NO336369B1 (en)
NZ (1) NZ564173A (en)
PL (2) PL2080522T3 (en)
PT (2) PT2080522E (en)
SG (1) SG163584A1 (en)
SI (2) SI2080522T1 (en)
TN (1) TNSN08001A1 (en)
WO (1) WO2007006939A2 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200701787A1 (en) 2005-03-23 2008-08-29 Глаксосмитклайн Байолоджикалс С.А. IMMUNE COMPOSITION, METHOD FOR ITS MANUFACTURE, ITS APPLICATION AND VACCINATION METHOD
AR054822A1 (en) * 2005-07-07 2007-07-18 Sanofi Pasteur ADMISSION IMMUNE EMULSION
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ567978A (en) * 2005-11-04 2011-09-30 Novartis Vaccines & Diagnostic Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
AU2011213757B2 (en) * 2005-11-04 2013-07-25 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
EP3714900A1 (en) 2005-11-04 2020-09-30 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
HRP20140488T1 (en) 2006-07-17 2014-07-04 Glaxosmithkline Biologicals S.A. Influenza vaccine
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
US9562075B2 (en) 2007-05-31 2017-02-07 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Intradermal HPV peptide vaccination
CN101428145B (en) * 2007-11-05 2013-01-02 北京生泰尔生物科技有限公司 Novel vaccine adjuvant
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
CN101959527B (en) 2008-03-05 2016-04-20 赛诺菲巴斯德有限公司 A method of stabilizing an adjuvanted vaccine composition
US20110150926A1 (en) 2008-08-01 2011-06-23 Mohammed Alsharifi Influenza vaccines
PL2396032T3 (en) 2009-02-10 2017-05-31 Seqirus UK Limited FLU VACCINES WITH REDUCED Squalene
DK2400951T3 (en) 2009-02-25 2018-12-03 Mayne Pharma Llc TOPICAL FOAM COMPOSITION
PH12012500694A1 (en) 2009-10-09 2012-10-29 Cbio Ltd Chaperonin 10 variants
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
GB201009673D0 (en) * 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
AU2011336366B2 (en) 2010-12-03 2016-05-12 Sanofi Pasteur Limited Composition for immunization against Streptococcus pneumoniae
US20140079732A1 (en) 2011-01-27 2014-03-20 Gamma Vaccines Pty Limited Combination vaccines
EP2578974A1 (en) 2011-10-05 2013-04-10 Sanofi Pasteur Sa Process line for the production of freeze-dried particles
EP2817286B1 (en) 2012-03-23 2018-06-06 Pitney Pharmaceuticals Pty Limited Kinase inhibitors for the treatment of cancer
CA2875683A1 (en) 2012-06-05 2013-12-12 The Australian National University Vaccination with interleukin-4 antagonists
WO2013184900A2 (en) 2012-06-06 2013-12-12 Sanofi Pasteur Biologics, Llc Immunogenic compositions and related methods
MY197723A (en) 2012-07-24 2023-07-10 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
WO2014016362A1 (en) 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
US9790176B2 (en) 2012-08-06 2017-10-17 Pitney Pharmaceuticals Pty Limited Compounds for the treatment of mTOR pathway related diseases
CN103784953B (en) * 2012-10-26 2018-04-10 上海医药工业研究院 Oil-in-water type Submicron Emulsion as vaccine adjuvant and preparation method thereof
WO2014083194A1 (en) 2012-11-30 2014-06-05 Sanofi Pasteur Methods for inducing antibodies
US11369666B2 (en) 2012-12-17 2022-06-28 Newsouth Innovations Pty Limited Treatment of diseases involving mucin
AU2013370932B2 (en) 2012-12-24 2019-02-21 Cell Ideas Pty Ltd Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
EP3016968B1 (en) 2013-07-01 2019-06-26 Newsouth Innovations Pty Limited Diagnosis and treatment of autoimmune diseases
CN105267963A (en) * 2014-06-18 2016-01-27 潘皓 Preparation method for nanoemulsion vaccine auxiliary agent
CN107073350B (en) 2014-07-21 2019-11-15 赛诺菲巴斯德股份公司 Liquid feeding device for producing droplets
CN107427569B (en) 2015-03-26 2022-12-30 Gpn疫苗有限公司 strep vaccine
CN105251002B (en) * 2015-11-13 2019-02-15 中国人民解放军第三军医大学 A kind of oil-in-water nanoemulsion adjuvant and MRSA nanoemulsion adjuvant vaccine and preparation method thereof
WO2017137085A1 (en) 2016-02-11 2017-08-17 Sanofi Pasteur Meningitidis vaccines comprising subtilinases
CN108697782A (en) * 2016-03-23 2018-10-23 英特维特国际股份有限公司 Combination vaccine against PCV2 virus and Mycoplasma hyopneumoniae infection
US12065482B2 (en) 2016-08-10 2024-08-20 Celltrion Inc. Stable liquid pharmaceutical formulation of anti-influenza virus antibody
IL269534B2 (en) 2017-03-30 2025-01-01 Univ Queensland Chimeric molecules and uses thereof
WO2021231729A1 (en) 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza
TW202219057A (en) 2020-08-24 2022-05-16 美商賽諾菲巴斯德公司 Novel vaccines against sars-cov-2 infections
AU2024228998A1 (en) 2023-03-02 2025-10-16 Sanofi Pasteur Compositions for use in treatment of chlamydia
CN118662475A (en) * 2023-03-16 2024-09-20 清华大学 Preparation and application of solidified self-microemulsified vaccine
AU2024267861A1 (en) 2023-05-05 2026-01-08 Sanofi Pasteur Inc. Compositions for use in treatment of acne
CN116531514A (en) * 2023-05-29 2023-08-04 大连理工大学 Application of alkyl glycoside surfactant in aluminum adjuvant freeze-drying

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
JP2607712B2 (en) 1988-01-29 1997-05-07 カイロン コーポレイション Recombinant CMV neutralizing protein
HU212924B (en) * 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2723740B1 (en) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc PROCESS FOR THE PREPARATION OF INFLUENZA VIRUS ANTIGENS, ANTIGENS OBTAINED AND THEIR APPLICATIONS
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
FR2773156B1 (en) 1997-12-26 2000-03-31 Biovacs Inc NOVEL ANTI-RETROVIRAL IMMUNOGENS (TOXOIDS), NOVEL PREPARATION METHODS AND APPLICATION TO AIDS PREVENTION AND TREATMENT
US6299848B1 (en) * 1998-09-25 2001-10-09 Hamon Research-Cottrell Process for removing sulfur dioxide out of a gas
AU764969B2 (en) * 1999-04-19 2003-09-04 Smithkline Beecham Biologicals (Sa) Vaccines
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
ATE444735T1 (en) * 2001-03-21 2009-10-15 Madash Llc THERMALLY REVERSIBLE WATER-IN-OIL-IN-WATER EMULSIONS
AR054822A1 (en) * 2005-07-07 2007-07-18 Sanofi Pasteur ADMISSION IMMUNE EMULSION

Also Published As

Publication number Publication date
PL1904099T3 (en) 2009-08-31
JP2009500382A (en) 2009-01-08
PL2080522T3 (en) 2012-11-30
NO336369B1 (en) 2015-08-10
JP5300475B2 (en) 2013-09-25
DK2080522T3 (en) 2012-10-08
SI1904099T1 (en) 2009-08-31
AU2006268466A1 (en) 2007-01-18
CA2613732C (en) 2013-12-10
WO2007006939A3 (en) 2007-04-05
DE602006005671D1 (en) 2009-04-23
ATE424845T1 (en) 2009-03-15
EA012376B1 (en) 2009-10-30
ES2390104T3 (en) 2012-11-06
CN101217977B (en) 2013-03-06
CY1113414T1 (en) 2016-06-22
KR101328638B1 (en) 2013-11-27
EP2080522A1 (en) 2009-07-22
CY1108994T1 (en) 2014-07-02
AU2006268466B2 (en) 2011-11-10
SI2080522T1 (en) 2012-10-30
SG163584A1 (en) 2010-08-30
AR054822A1 (en) 2007-07-18
PT1904099E (en) 2009-05-29
CA2613732A1 (en) 2007-01-18
EP2080522B1 (en) 2012-07-04
PT2080522E (en) 2012-10-01
NZ564173A (en) 2010-10-29
TNSN08001A1 (en) 2009-07-14
EA200800271A1 (en) 2008-04-28
IL187967A0 (en) 2008-03-20
EP1904099B1 (en) 2009-03-11
DK1904099T3 (en) 2009-06-08
CN101217977A (en) 2008-07-09
MX2007016412A (en) 2008-03-07
ES2322102T3 (en) 2009-06-16
EP1904099A2 (en) 2008-04-02
WO2007006939A2 (en) 2007-01-18
BRPI0614053A2 (en) 2011-03-09
KR20080030076A (en) 2008-04-03

Similar Documents

Publication Publication Date Title
NO20080585L (en) Immunological adjuvant emulsion
NO20054376L (en) Microfluidized oil-in-water emulsions and vaccine mixtures
JP2009500382A5 (en)
BR9510223A (en) Adjuvant for vaccines use of a lipid polysaccharide process to prepare an emulsion and vaccine cacina
BRPI0000126B8 (en) vaccine composition, adjuvant composition and method of producing a vaccine composition
WO2007052155A3 (en) Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
DK2268823T3 (en) Preparation of squalene from hyper-producing yeasts
WO2007052061A3 (en) Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
CY1112572T1 (en) Influenza Vaccines Containing Particulate Immunosuppressants and Immunosuppressants
WO2007098186A3 (en) Adjuvant and vaccine compositions
EA200901161A1 (en) VACCINE AGAINST THE FLU IN THE FORM OF THE TYPE "OIL IN WATER" EMULSION
PE20201443A1 (en) AN IMMUNOGENIC COMPOSITION THAT HAS IMPROVED STABILITY, ENHANCED IMMUNOGENEICITY AND REDUCED REACTOGENICITY AND PROCESS FOR THE PREPARATION OF THE SAME
NO20081033L (en) Reduction of interference between oil-containing adjuvants and surfactant-containing antigens
Harmsen et al. Stabilizing effects of excipients on dissociation of intact (146S) foot-and-mouth disease virions into 12S particles during storage as oil-emulsion vaccine
RU2017124240A (en) METHOD FOR OBTAINING READY TO USE COMBINED VACCINE AGAINST PCV2 / M.hyo
FI842215A0 (en) FOERFARANDE FOER FRAMSTAELLNING AV LEVANDE EFFEKTIVERINGSVACCIN OCH PAO DETTA SAETT ERHAOLLNA VACCIN.
NO20074679L (en) Adjuvant composition comprising aluminum scaffold and 3D MPL
UY26882A1 (en) NEW TREATMENT
Kumar Immunizations following solid-organ transplantation
GB2534038A (en) Oil-in-water stable, emulsified spacer fluids
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
ATE412040T1 (en) PRODUCTION PROCESS FOR LIQUID CRYSTAL EMULSION COMPOSITIONS
ATE423828T1 (en) PRODUCTION PROCESS FOR LIQUID CRYSTAL EMULSION COMPOSITIONS
ATE303821T1 (en) NEW VACCINE FORMULATION FROM DNA VACCINE-INACTIVATED VIRUS
NO20090035L (en) Orally encapsulated preparation for aquatic animals, method of preparation thereof, and use thereof

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees